PMID- 10591869
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20190726
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 147
IP  - 1
DP  - 1999 Nov
TI  - Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 
      3,4-methylenedioxymethamphetamine (MDMA) users.
PG  - 56-65
AB  - RATIONALE: (+/-) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is a popular 
      drug of abuse and a brain serotonin neurotoxin in animals. Growing evidence 
      indicates that humans are also susceptible to MDMA's neurotoxic effects, although 
      few functional consequences of MDMA-induced 5-HT damage have been identified. 
      OBJECTIVE: The present study sought to determine whether possible differences 
      between MDMA users and control subjects could be unmasked by utilizing a 
      pharmacological challenge with the mixed 5-HT agonist, 
      meta-chlorophenylpiperazine (m-CPP). It was postulated that 5-HT neurotoxicity in 
      MDMA users would be associated with altered 5-HT responsivity, exemplified by 
      altered physiological and behavioral responses to m-CPP. METHODS: Twenty-five 
      MDMA users who had not taken MDMA for at least 3 weeks and 25 controls received 
      intravenous placebo (normal saline) and m-CPP (0.08 mg/kg) in a fixed order, 
      single blind design. Repeated measures of mood, physical symptoms, and blood 
      samples for neuroendocrine analyses were collected during the 90 min after each 
      infusion. RESULTS: MDMA users reported more positive and fewer negative emotions 
      and physical symptoms following m-CPP than controls, and were significantly less 
      likely to report an m-CPP-induced panic attack. Male MDMA users had diminished 
      cortisol and prolactin responses to m-CPP. CONCLUSIONS: The present data indicate 
      that MDMA users have alterations in 5-HT neuronal function, possibly as a 
      consequence of MDMA-induced brain serotonin neural injury.
FAU - McCann, U D
AU  - McCann UD
AD  - Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 
      20892-1272, USA. umccann@helix.nih.gov
FAU - Eligulashvili, V
AU  - Eligulashvili V
FAU - Mertl, M
AU  - Mertl M
FAU - Murphy, D L
AU  - Murphy DL
FAU - Ricaurte, G A
AU  - Ricaurte GA
LA  - eng
GR  - DA00206/DA/NIDA NIH HHS/United States
GR  - DA05707/DA/NIDA NIH HHS/United States
GR  - DA05938/DA/NIDA NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Hallucinogens)
RN  - 0 (Piperazines)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 333DO1RDJY (Serotonin)
RN  - 9002-62-4 (Prolactin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - REY0CNO998 (1-(3-chlorophenyl)piperazine)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Affect/drug effects
MH  - Anxiety/psychology
MH  - Behavior/*drug effects
MH  - Female
MH  - Hallucinogens/*adverse effects
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Neurosecretory Systems/*drug effects
MH  - *Piperazines/blood
MH  - Prolactin/blood
MH  - Serotonin/*physiology
MH  - *Serotonin Receptor Agonists/blood
MH  - Single-Blind Method
EDAT- 1999/12/11 00:00
MHDA- 1999/12/11 00:01
CRDT- 1999/12/11 00:00
PHST- 1999/12/11 00:00 [pubmed]
PHST- 1999/12/11 00:01 [medline]
PHST- 1999/12/11 00:00 [entrez]
AID - 91470056.213 [pii]
AID - 10.1007/s002130051142 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 1999 Nov;147(1):56-65. doi: 10.1007/s002130051142.